SEARCH

SEARCH BY CITATION

References

  • 1
    Lairmore MD,Franchini G. Human T-cell leukemia virus types I and II. In: KnipeDM,HowleyPM, eds. Fields virology,5th edn. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007. 2072105.
  • 2
    International Agency for Research on Cancer (IARC). Human T-cell lymphotropic viruses. In:IARC. monographs on the evaluation of carcinogenic risks to humans, Vol 67. Lyon: IARC, 1996. 261390.
  • 3
    Mueller N,Birmann B,Parsonnet J,Schiffman M,Stuver S. Infectious agents. In: SchottenfeldD,FraumeniJJ, eds. Cancer epidemiology and prevention,3rd edn. New York: Oxford University Press, 2006. 50748.
  • 4
    Mortreux F,Gabet AS,Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 2003; 17: 2638.
  • 5
    Li HC,Walters M,Carrington M,Headley C,Amarasinghe A,Goedert J,Cranston B,Hanchard B,Hisada M. Serologic and molecular characteristics of atypical HTLV Western blot banding patterns in Jamaican blood donors [Abstract P56]. AIDS Res Hum Retroviruses 2005; 21: 479.
  • 6
    Barmak K,Harhaj E,Grant C,Alefantis T,Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 2003; 308: 112.
  • 7
    Lucey DR,Clerici M,Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9: 53262.
  • 8
    Akimoto M,Kozako T,Sawada T,Matsushita K,Ozaki A,Hamada H,Kawada H,Yoshimitsu M,Tokunaga M,Haraguchi K,Uozumi K,Arima N, et al. Anti-HTLV-I Tax antibody and Tax-specific cytotoxic T-lymphocyte are associated with a reduction in HTLV-I proviral load in asymptomatic carriers. J Med Virol 2007; 79: 97786.
  • 9
    Mueller N,Okayama A,Stuver S,Tachibana N. Findings from the Miyazaki Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13( Suppl 1): S2S7.
  • 10
    Yokota T,Cho MJ,Tachibana N,McLane MF,Takatsuki K,Lee TH,Mueller N,Essex M. The prevalence of antibody to p42 of HTLV-I among ATLL patients in comparison with healthy carriers in Japan. Int J Cancer 1989; 43: 9704.
  • 11
    Kubota R,Nagai M,Kawanishi T,Osame M,Jacobson S. Increased HTLV type 1 tax specific CD8+ cells in HTLV type 1-asociated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load. AIDS Res Hum Retroviruses 2000; 16: 17059.
  • 12
    Nagai M,Kubota R,Greten TF,Schneck JP,Leist TP,Jacobson S. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11–19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 2001; 183: 197205.
  • 13
    Imai J,Hinuma Y. Epstein-Barr virus-specific antibodies in patients with adult T-cell leukemia (ATL) and healthy ATL virus-carriers. Int J Cancer 1983; 31: 197200.
  • 14
    Tendler CL,Greenberg SJ,Burton JD,Danielpour D,Kim SJ,Blattner WA,Manns A,Waldmann TA. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. J Cell Biochem 1991; 46: 30211.
  • 15
    Hisada M,Stuver SO,Okayama A,Li HC,Sawada T,Hanchard B,Mueller NE. Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. J Infect Dis 2004; 190: 16059.
  • 16
    Birmann BM,Mueller NE,Okayama A,Hsieh CC,Tsubouchi H,Harn D,Stuver SO. Patterns of serum type 1 and type 2 immune markers in healthy carriers of HTLV-I. J Med Virol 2006; 78: 84752.
  • 17
    Tachibana N,Okayama A,Ishizaki J,Yokota T,Shishime E,Murai K,Shioiri S,Tsuda K,Essex M,Mueller N. Suppression of tuberculin skin reaction in healthy HTLV-I carriers from Japan. Int J Cancer 1988; 42: 82931.
  • 18
    Murai K,Tachibana N,Shioiri S,Shishime E,Okayama A,Ishizaki J,Tsuda K,Mueller N. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J Acquir Immune Defic Syndr 1990; 3: 10069.
  • 19
    Kwon KW. Epstein-Barr virus-specific immunity in asymptomatic carriers of human T-cell leukemia virus type 1. Hokkaido Igaku Zasshi 1995; 70: 31528.
  • 20
    Murphy EL,Figueroa JP,Gibbs WN,Holding-Cobham M,Cranston B,Malley K,Bodner AK,Alexander SS,Blattner WA. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol 1991; 133: 111424.
  • 21
    Sawada T,Tohmatsu J,Obara T,Koide A,Kamihira S,Ichimaru M,Kashiwaqi S,Kajiyama W,Matsumura N,Kinoshita K,Yano M,Yamaguchi K, et al. High risk of mother-to-child transmission of HTLV-I in p40tax antibody-positive mothers. Jpn J Cancer Res 1989; 80: 5068.
  • 22
    Lennette ET,Rymo L,Yadav M,Masucci G,Merk K,Timar L,Klein G. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 1993; 29A: 15849.
  • 23
    Nagy N,Maeda A,Bandobashi K,Kis LL,Nishikawa J,Trivedi P,Faggione A,Klein G,Klein E. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation. Int J Cancer 2002; 100: 43340.
  • 24
    Linde A,Andersson J,Lundgren G,Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol 1987; 21: 10921.
  • 25
    Rubin LA,Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990; 113: 61927.
  • 26
    Younes A,Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003; 98: 45867.
  • 27
    Fernandez-Real JM,Vayreda M,Richart C,Gutierrez C,Broch M,Vendrell J,Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001; 86: 11549.
  • 28
    Hoffmann G,Wirleitner B,Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003; 52: 31321.
  • 29
    Henle W,Henle G,Andersson J,Ernberg I,Klein G,Horwitz CA,Marklund G,Rymo L,Wellinder C,Straus SE. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987; 84: 5704.
  • 30
    Aziz N,Nishanian P,Fahey JL. Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures. Clin Diagn Lab Immunol 1998; 5: 75561.
  • 31
    Whiteside TL. Cytokine measurements and interpretation of cytokine assays in human disease. J Clin Immunol 1994; 14: 32739.
  • 32
    Birmann BM,Mueller N,Okayama A,Hsieh CC,Tachibana N,Tsubouchi H,Lennette ET,Harn D,Stuver S. Serologic assessment of type 1 and type 2 immunity in healthy Japanese adults. Cancer Epidemiol Biomarkers Prev 2004; 13: 138591.
  • 33
    Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 110.
  • 34
    Ridker PM,Buring JE,Cook NR,Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 3917.
  • 35
    Yamamura M,Yamada Y,Momita S,Kamihira S,Tomonaga M. Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 1998; 100: 12934.
  • 36
    Yamashita I,Katamine S,Moriuchi R,Nakamura Y,Miyamoto T,Eguchi K,Nagataki S. Transactivation of the human interleukin-6 gene by human T-lymphotropic virus type 1 Tax protein. Blood 1994; 84: 15738.
  • 37
    Stein H,Mason DY,Gerdes J,O'Connor N,Wainscoat J,Pallesen G,Gatter K,Falini B,Delsol G,Lemke H,Schwarting R,Lennert K. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 84858.
  • 38
    Araki K,Harada K,Nakamoto K,Shiroma M,Miyakuni T. Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers. Clin Exp Immunol 2000; 119: 25963.
  • 39
    Arisawa K,Katamine S,Kamihira S,Kurokawa K,Sawada T,Soda M,Doi H,Saito H,Shirahama S. A nested case-control study of risk factors for adult T-cell leukemia/lymphoma among human T-cell lymphotropic virus type-I carriers in Japan. Cancer Causes Control 2002; 13: 65763.
  • 40
    Pfreundschuh M,Pohl C,Berenbeck C,Schroeder J,Jung W,Schmits R,Tschiersch A,Diehl V,Gause A. Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. Int J Cancer 1990; 45: 86974.
  • 41
    Dallenbach F,Josimovic-Alasevic O,Dürkop H,Schwarting R,Diamantstein T,Matsuoka M,Takatsuki K,Stein H. Soluble CD30 antigen in the sera of patients with adult T-cell lymphoma/leukemia (ATL): a marker for disease activity. In: KnappW,DorkenB,GilksWR,RieberEP,SchmidtRE,SteinH,von dem BorneAEG, eds. Leukocyte typing IV. Oxford, UK: Oxford University, 1989. 4268.
  • 42
    Tendler CL,Greenberg SJ,Blattner WA,Manns A,Murphy E,Fleisher T,Hanchard B,Morgan O,Burton JD,Nelson DL,Waldmann TA. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci USA 1990; 87: 521822.
  • 43
    Giusti RM,Maloney EM,Hanchard B,Morgan OS,Steinberg SM,Wachter H,Williams E,Cranston B,Fuchs D,Manns A. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prev 1996; 5: 699704.
  • 44
    Hayashi J,Kishihara Y,Yoshimura E,Furusyo N,Yamaji K,Kawakami Y,Murakami H,Kashiwaqi S. Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. Am J Trop Med Hyg 1997; 56: 715.
  • 45
    Matsumoto T,Miike T,Mizoguchi K,Yamaguchi K,Takatsuki K,Hosoda M,Kawabe T,Yodoi J. Decreased serum levels of IgE and IgE-binding factors in individuals infected with HTLV-I. Clin Exp Immunol 1990; 81: 20711.